86 related articles for article (PubMed ID: 27677395)
1. Developing a predictive risk model for first-line antiretroviral therapy failure in South Africa.
Rohr JK; Ive P; Horsburgh CR; Berhanu R; Shearer K; Maskew M; Long L; Sanne I; Bassett J; Ebrahim O; Fox MP
J Int AIDS Soc; 2016; 19(1):20987. PubMed ID: 27677395
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of treatment outcomes for patients on first-line regimens in US President's Emergency Plan for AIDS Relief (PEPFAR) clinics in Uganda: predictors of virological and immunological response from RV288 analyses.
Crawford KW; Wakabi S; Magala F; Kibuuka H; Liu M; Hamm TE
HIV Med; 2015 Feb; 16(2):95-104. PubMed ID: 25124078
[TBL] [Abstract][Full Text] [Related]
3. The relation between efavirenz versus nevirapine and virologic failure in Johannesburg, South Africa.
Shearer K; Brennan AT; Maskew M; Long L; Berhanu R; Sanne I; Fox MP
J Int AIDS Soc; 2014; 17(1):19065. PubMed ID: 25361827
[TBL] [Abstract][Full Text] [Related]
4. Treatment Failure in HIV-Infected Children on Second-line Protease Inhibitor-Based Antiretroviral Therapy.
Suaysod R; Ngo-Giang-Huong N; Salvadori N; Cressey TR; Kanjanavanit S; Techakunakorn P; Krikajornkitti S; Srirojana S; Laomanit L; Chalermpantmetagul S; Lallemant M; Le Cœur S; McIntosh K; Traisathit P; Jourdain G
Clin Infect Dis; 2015 Jul; 61(1):95-101. PubMed ID: 25838288
[TBL] [Abstract][Full Text] [Related]
5. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
6. Clinical and socio-demographic predictors for virologic failure in rural Southern Africa: preliminary findings from CART-1.
Labhardt ND; Bader J; Ramoeletsi M; Kamele M; Lejone TI; Cheleboi M; Motlatsi MM; Ehmer J; Faturyiele O; Puga D; Klimkait T
J Int AIDS Soc; 2014; 17(4 Suppl 3):19666. PubMed ID: 25397416
[TBL] [Abstract][Full Text] [Related]
7. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
8. Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
Orrell C; Harling G; Lawn SD; Kaplan R; McNally M; Bekker LG; Wood R
Antivir Ther; 2007; 12(1):83-8. PubMed ID: 17503751
[TBL] [Abstract][Full Text] [Related]
9. Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic.
Wilhelmson S; Reepalu A; Balcha TT; Jarso G; Björkman P
Glob Health Action; 2016; 9():29943. PubMed ID: 26765104
[TBL] [Abstract][Full Text] [Related]
10. Profile of HIV-infected patients receiving second-line antiretroviral therapy in a resource-limited setting in Nigeria.
Onyedum CC; Iroezindu MO; Chukwuka CJ; Anyaene CE; Obi FI; Young EE
Trans R Soc Trop Med Hyg; 2013 Oct; 107(10):608-14. PubMed ID: 23959002
[TBL] [Abstract][Full Text] [Related]
11. A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy.
Newman H; Breunig L; van Zyl G; Stich A; Preiser W
J Clin Virol; 2014 Aug; 60(4):387-91. PubMed ID: 24929754
[TBL] [Abstract][Full Text] [Related]
12. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.
Pujades-Rodríguez M; Balkan S; Arnould L; Brinkhof MA; Calmy A;
JAMA; 2010 Jul; 304(3):303-12. PubMed ID: 20639564
[TBL] [Abstract][Full Text] [Related]
13. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
14. Public-sector ART in the Free State Province, South Africa: community support as an important determinant of outcome.
Wouters E; Van Damme W; Van Loon F; van Rensburg D; Meulemans H
Soc Sci Med; 2009 Oct; 69(8):1177-85. PubMed ID: 19692165
[TBL] [Abstract][Full Text] [Related]
15. Baseline HIV-1 resistance, virological outcomes, and emergent resistance in the SECOND-LINE trial: an exploratory analysis.
Boyd MA; Moore CL; Molina JM; Wood R; Madero JS; Wolff M; Ruxrungtham K; Losso M; Renjifo B; Teppler H; Kelleher AD; Amin J; Emery S; Cooper DA;
Lancet HIV; 2015 Feb; 2(2):e42-51. PubMed ID: 26424460
[TBL] [Abstract][Full Text] [Related]
16. Development and external validation of a prognostic model for survival of people living with HIV/AIDS initiating antiretroviral therapy.
Wang J; Yuan T; Ding H; Xu J; Keusters WR; Ling X; Fu L; Zhu Q; Li Q; Tang X; Cai W; Shang H; Li L; Zou H
Lancet Reg Health West Pac; 2021 Nov; 16():100269. PubMed ID: 34590068
[No Abstract] [Full Text] [Related]
17. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
Bock P; Fatti G; Grimwood A
Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
[TBL] [Abstract][Full Text] [Related]
18. Predictors of first line antiretroviral therapy failure and burden of second line antiretroviral therapy.
Patrikar S; Shankar S; Kotwal A; Basannar DR; Bhatti V; Verma R; Mukherji S
Med J Armed Forces India; 2017 Jan; 73(1):5-11. PubMed ID: 28123238
[TBL] [Abstract][Full Text] [Related]
19. Comparison of machine learning methods for predicting viral failure: a case study using electronic health record data.
Kimaina A; Dick J; DeLong A; Chrysanthopoulou SA; Kantor R; Hogan JW
Stat Commun Infect Dis; 2020 Sep; 12(Suppl1):20190017. PubMed ID: 37288469
[TBL] [Abstract][Full Text] [Related]
20. Patient- and population-level health consequences of discontinuing antiretroviral therapy in settings with inadequate HIV treatment availability.
Kimmel AD; Resch SC; Anglaret X; Daniels N; Goldie SJ; Danel C; Wong AY; Freedberg KA; Weinstein MC
Cost Eff Resour Alloc; 2012 Sep; 10(1):12. PubMed ID: 22992315
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
